Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Shares of hepatitis C drug developers rise on Bristol-Myers' $2.5B deal for Inhibitex
Shares of hepatitis C drug developers rise on Bristol-Myers' $2.5B deal for Inhibitex
Shares of hepatitis C drug developers rise on Bristol-Myers' $2.5B deal for Inhibitex
Submitted by
admin
on January 9, 2012 - 9:57am
Source:
Yahoo/AP
News Tags:
hepatitis C
Bristol-Myers Squibb
M&A
Inhibitex
Gilead
Pharmasset
Headline:
Shares of hepatitis C drug developers rise on Bristol-Myers' $2.5B deal for Inhibitex
Do Not Allow Advertisers to Use My Personal information
